Suppr超能文献

用于检测老年人心力衰竭的B型利钠肽检测:与年轻人的检测价值相同吗?

B-type natriuretic peptide assays for detecting heart failure in the elderly: same value as those in the younger?

作者信息

Rutten Frans H, Hoes Arno W

机构信息

Utrecht Heart Failure Organisation (UHFO), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO Box 85060, Stratenum 6.131, 3508 AB Utrecht, The Netherlands.

出版信息

Int J Cardiol. 2008 Apr 10;125(2):161-5. doi: 10.1016/j.ijcard.2007.10.006. Epub 2007 Oct 25.

Abstract

Establishing a diagnosis of heart failure in elderly patients is notoriously difficult, especially in those who experience slowly progressive breathlessness, have multiple co-morbidity, and when, as in primary care echocardiography is not routinely (or readily) available. B-type natriuretic peptides measurements are useful in the diagnostic assessment of such patients, although the evidence in the very old (i.e. those aged 75 years and over) is less clear than for younger patients. Conflicting results in literature regarding B-type natriuretic peptides are mainly caused by differences in assays, the applied 'gold standard' for heart failure, and the population studied. Moreover, there is no consensus as to whether similar cut-off points should be applied across age-groups. Numerous studies showed that plasma levels of B-type natriuretic peptide are elevated in the elderly, including the 'healthy' ones. Age-related myocardial fibrosis and subtle diastolic dysfunction that are not detectable by current techniques, and reduced renal clearance have been suggested as reasons for this phenomenon. Importantly, B-type natriuretic peptides are not specific for heart failure, but reflect haemodynamic myocardial stress independent of the underlying pathology, and thus are more 'markers' of the general cardiac state. Cut-points differ widely when comparing studies in patients with acute versus chronic dyspnoea. In patients with acute dyspnoea age-dependent cut-points should be used, while in patients with chronic dyspnoea (that is, slowly progressive breathlessness) at least thresholds below which heart failure can be excluded seem rather independent of age. Especially in the primary care setting where elderly patients with slowly progressive dyspnoea are investigated, the excellent exclusionary capacities of B-type natriuretic peptides are of great help to select those that require echocardiography to establish or eventually reject a diagnosis of heart failure.

摘要

在老年患者中确诊心力衰竭非常困难,尤其是对于那些经历缓慢进展性呼吸困难、患有多种合并症且在基层医疗中无法常规(或轻易)获得超声心动图检查的患者。B型利钠肽检测对于此类患者的诊断评估很有用,尽管在高龄患者(即75岁及以上)中的证据不如年轻患者那么明确。文献中关于B型利钠肽的结果相互矛盾,主要是由于检测方法、应用的心力衰竭“金标准”以及所研究人群的差异。此外,对于是否应在不同年龄组应用相似的临界值尚无共识。大量研究表明,包括“健康”老年人在内,老年人血浆B型利钠肽水平都会升高。年龄相关的心肌纤维化和目前技术无法检测到的轻微舒张功能障碍以及肾清除率降低被认为是这一现象的原因。重要的是,B型利钠肽并非心力衰竭所特有,而是反映与潜在病理无关的血流动力学心肌应激,因此更多是一般心脏状态的“标志物”。比较急性与慢性呼吸困难患者的研究时,临界值差异很大。对于急性呼吸困难患者,应使用与年龄相关的临界值,而对于慢性呼吸困难患者(即缓慢进展性呼吸困难),至少低于该临界值可排除心力衰竭,这似乎与年龄无关。特别是在对患有缓慢进展性呼吸困难的老年患者进行调查的基层医疗环境中,B型利钠肽出色的排除能力有助于选择那些需要超声心动图检查来确诊或最终排除心力衰竭诊断的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验